Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOOP: Rivaroxaban in CABG
NCT03605433Phase 3Unknown
- Sponsor
- ULS Coimbra
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban in coronary artery disease (CAD) (3 arms), sponsored by ULS Coimbra. Primary endpoints: Major Adverse Cardiovascular Events at 5 years, Saphenous Vein Graft Patency at 5 years and 1 more. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03605433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605433.